NewLink jump-starts a Zika vaccine program as virus spreads

NewLink Genetics ($NLNK), which partnered with Merck ($MRK) on a promising Ebola program, has joined the incipient race to find a vaccine that can be used to combat the recent spread of the Zika virus. Inovio, Hawaii Biotech and other small biotechs have already piled in. "NewLink Genetics is committed to developing a vaccine solution to the tragedy of the Zika virus disease," said Thomas Monath, the CSO at NewLink. "Our R&D group has decades of experience in developing successful vaccines against closely-related flaviviruses, which we will leverage to accelerate our Zika vaccine program." Its shares jumped 5% this morning. Release

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.